AXT, Inc. Third Quarter 2026 Earnings Call - AXT INC

Financial Performance:

• Q3 2026 revenue reached $73.4 million, a 54% sequential increase (from $47.6M in Q2 2026) and a 162% year-over-year increase (from $28.0M in Q3 2025).
• Revenue breakdown: Indium Phosphide ($54.3M, driven by data center demand), Gallium Arsenide ($9.1M), Germanium Substrates ($344k), and consolidated raw materials ($9.7M).
• Non-GAAP gross margin improved significantly to 56.1% (vs. 45.0% in Q2 2026 and 22.4% in Q3 2025), driven by volume growth, favorable product mix, wafer size migration (3-inch to 4-inch), and higher Indium Phosphide prices.
• Non-GAAP operating profit was $29.5 million (40.2% of revenue), compared to a loss of $384k in Q3 2025; Non-GAAP net profit was $26.8 million ($0.41 per diluted share).
• Cash, cash equivalents, and investments increased $77 million to $825.9 million as of September 30, 2026.
• Days Sales Outstanding (DSO) improved to 49 days due to a $43.5 million prepayment from a Lumentum long-term supply agreement, recorded as a liability.
• Non-GAAP operating expenses rose to $11.7 million (vs. $6.7 million in Q3 2025) to support expansion efforts.

Guidance and Future Outlook:

• Q4 2026 revenue guidance is set at approximately $90 million, with high confidence in recognition based on existing permits or permit-free shipments.
• Q4 Non-GAAP net income is guided to $0.57–$0.59 per share; GAAP net income is guided to $0.56–$0.58 per share.
• Management anticipates gross margins will continue to rise, potentially exceeding 60% in the near future as volume scales and 6-inch wafer production ramps up.
• Indium Phosphide capacity is expected to nearly triple by the end of 2026 compared to end-2025 levels, with a further doubling planned for 2027.
• Backlog has surged to over $500 million (up from >$100 million in Q2), comprising multi-year agreements, short-term contracts, and spot orders extending into 2027.
• Long-term revenue opportunity for Indium Phosphide has quadrupled in 2026 and is expected to continue growing in 2027.

Business Segments and Product Lines:

• Indium Phosphide: Dominates revenue growth; transitioning from 3-inch to 4-inch and pilot production of 6-inch wafers is underway. New proprietary crystal growth furnaces are enhancing productivity and enabling scale.
• Gallium Arsenide: Demand growing for slow-sweep and wide-VIXO lasers based on 6-inch and 8-inch substrates in data center and wireless applications; company maintains leadership in large-diameter substrates.
• Raw Materials: Subsidiary Jingmei is refining high-purity Indium, securing supply chain control and expanding capacity to support Indium Phosphide growth.
• Subsidiary Development: Majority-owned subsidiary Tongmei secured private equity financing (potential $545M) to expand Indium Phosphide and raw material capacity in China, targeting a Hong Kong IPO.
• Customer Agreements: Signed a major long-term supply agreement with Lumentum ($43.5M prepayment); multiple customers are increasing order volumes by 2x to 3x due to supply constraints.

Market and Competitive Landscape:

• AI data center build-out is driving unprecedented demand for high-speed optical connectivity (800G/1.6T transceivers), creating a supply-demand imbalance in Indium Phosphide substrates.
• Market is shifting toward co-packaged optics (CPO) and near-packaged optics, further increasing reliance on AXT materials.
• Competitive barriers are high due to technical complexity in crystal growth; AXT leads in low Effective Photoluminescence (EPD) defect density and large-diameter wafer capability.
• Six-inch Indium Phosphide production is currently dominated by AXT and one other peer; AXT is the only one aggressively scaling capacity with new furnace technology.
• China is emerging as a significant growth market with increasing demand for laser applications, facilitated by exports not requiring permits.

Risks and Challenges:

• Supply Constraints: Current demand significantly outpaces supply, with all customers on allocation and lead times extending beyond nine months.
• Regulatory/Geopolitical: Risks regarding trade tariffs, export restrictions, and the ability to obtain China export permits for certain shipments.
• Execution Risk: Scaling 6-inch production involves initial yield challenges, though management expects rapid improvement.
• Cost Pressures: Rising raw material prices for Indium Phosphide could impact margins, though offset by efficiency gains and ASP increases.

Management Commentary and Tone:

• Tone is highly confident and bullish, describing the current phase as a "pivotal" inflection point with a "transformational growth" trajectory.
• CEO Morris Young noted they did not anticipate the market size to be so large, stating demand is growing "faster than we can add capacity."
• Management emphasized strategic focus on capacity expansion, productivity gains, and maintaining flexibility (avoiding locking in too many long-term contracts) to maximize ASP and margin potential.
• CFO Gary Fisher expressed no concern regarding overcapacity risks for 2027 or 2028, viewing current Capex plans as reasonable given the demand trajectory.

Analyst Questions and Answers:

• Gross Margins: Analysts asked about margin ceilings; management confirmed margins will likely exceed 60% soon, driven by 6-inch ramp, new furnaces, and high-EPD requirements.
• Capacity & Overcapacity: Regarding fears of Indium Phosphide overcapacity, management stated the company is "overbooked" and cannot keep up with demand; they do not foresee overcapacity through 2027.
• Backlog Composition: Management clarified that the $500M+ backlog is driven primarily by run-rate spot orders and annual contracts rather than long-term agreements, allowing for pricing flexibility.
• Wafer Transition: 3-inch remains dominant now, but 4-inch is expected to match 3-inch volume by end of 2026; 6-inch pilot production is starting with significant yield growth expected in 2027.
• Competitors: Only two players are competitive in 6-inch (AXT and S), with AXT leading in capacity scale and defect density.

Other Key Points:

• AXT retains 73.4% ownership of Tongmei post-financing, maintaining control despite dilution.
• The company is in the design phase to convert an adjacent building for Indium Phosphide production.
• Management highlighted that the transition to 6-inch wafers represents a step-change in revenue potential and competitive differentiation.
• The company plans to attend UBS, Northland, and Needham conferences in late 2026/early 2027.